Hanson & Doremus Investment Management’s AbbVie ABBV Stock Holding History

Hanson & Doremus Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.17M	Buy	16,581 +883	+6%	+$190K	0.42%	35
2026 Q1	$3.41M	Sell	15,698 -315	-2%	-$69.9K	0.39%	42
2025 Q4	$3.66M	Sell	16,013 -14	-0.1%	-$3.19K	0.44%	36
2025 Q3	$3.71M	Buy	16,027 +103	+0.6%	+$21K	0.47%	35
2025 Q2	$2.96M	Sell	15,924 -57	-0.4%	-$10.6K	0.4%	46
2025 Q1	$3.35M	Buy	15,981 +7,126	+80%	+$1.39M	0.49%	39
2024 Q4	$1.57M	Buy	8,855 +1,536	+21%	+$282K	0.25%	61
2024 Q3	$1.45M	Sell	7,319 -50	-0.7%	-$9.33K	0.23%	64
2024 Q2	$1.26M	Sell	7,369 -119	-2%	-$19.7K	0.21%	66
2024 Q1	$1.36M	Sell	7,488 -261	-3%	-$45K	0.24%	65
2023 Q4	$1.2M	Sell	7,749 -99	-1%	-$14.4K	0.23%	74
2023 Q3	$1.17M	Buy	7,848 +288	+4%	+$42.3K	0.24%	74
2023 Q2	$1.02M	Sell	7,560 -551	-7%	-$80.8K	0.21%	77
2023 Q1	$1.29M	Sell	8,111 -590	-7%	-$90.2K	0.29%	66
2022 Q4	$1.41M	Sell	8,701 -577	-6%	-$88.5K	0.3%	65
2022 Q3	$1.25M	Buy	9,278 +288	+3%	+$41.3K	0.32%	63
2022 Q2	$1.38M	Buy	8,990 +21	+0.2%	+$3.21K	0.34%	63
2022 Q1	$1.45M	Buy	8,969 +1,464	+20%	+$213K	0.31%	65
2021 Q4	$1.02M	Sell	7,505 -239	-3%	-$28.2K	0.22%	83
2021 Q3	$835K	Sell	7,744 -145	-2%	-$16.6K	0.19%	93
2021 Q2	$691K	Sell	7,889 -159	-2%	-$17.9K	0.21%	89
2021 Q1	$871K	Sell	8,048 -48	-0.6%	-$5.13K	0.2%	97
2020 Q4	$867K	Buy	8,096 +207	+3%	+$19.9K	0.22%	90
2020 Q3	$691K	Sell	7,889 -61	-0.8%	-$5.74K	0.21%	89
2020 Q2	$781K	Sell	7,950 -786	-9%	-$69.2K	0.25%	81
2020 Q1	$666K	Buy	8,736 +700	+9%	+$59.6K	0.23%	85
2019 Q4	$712K	Buy	8,036 +1,000	+14%	+$83K	0.2%	97
2019 Q3	$533K	Sell	7,036 -317	-4%	-$21.7K	0.17%	106
2019 Q2	$535K	Buy	7,353 +1,200	+20%	+$94.3K	0.17%	103
2019 Q1	$496K	Buy	6,153 +103	+2%	+$8.43K	0.16%	112
2018 Q4	$558K	Hold	6,050	–	–	0.2%	96
2018 Q3	$572K	Sell	6,050 -237	-4%	-$22.5K	0.18%	110
2018 Q2	$582K	Sell	6,287 -1,003	-14%	-$98K	0.19%	108
2018 Q1	$690K	Buy	7,290 +501	+7%	+$55K	0.21%	103
2017 Q4	$657K	Hold	6,789	–	–	0.22%	103
2017 Q3	$603K	Buy	6,789 +1,180	+21%	+$89.8K	0.21%	109
2017 Q2	$407K	Buy	5,609 +57	+1%	+$3.83K	0.15%	125
2017 Q1	$362K	Sell	5,552 -110	-2%	-$6.92K	0.14%	127
2016 Q4	$355K	Hold	5,662	–	–	0.15%	123
2016 Q3	$357K	Hold	5,662	–	–	0.17%	122
2016 Q2	$351K	Buy	5,662 +35	+0.6%	+$2.13K	0.16%	125
2016 Q1	$321K	Hold	5,627	–	–	0.15%	128
2015 Q4	$333K	Hold	5,627	–	–	0.15%	127
2015 Q3	$306K	Sell	5,627 -200	-3%	-$13K	0.15%	131
2015 Q2	$392K	Hold	5,827	–	–	0.17%	128
2015 Q1	$341K	Hold	5,827	–	–	0.14%	135
2014 Q4	$381K	Sell	5,827 -195	-3%	-$12.3K	0.16%	132
2014 Q3	$348K	Sell	6,022 -200	-3%	-$11.1K	0.16%	137
2014 Q2	$351K	Sell	6,222 -783	-11%	-$41.1K	0.16%	138
2014 Q1	$360K	Sell	7,005 -200	-3%	-$10.1K	0.17%	132
2013 Q4	$380K	Sell	7,205 -471	-6%	-$23.1K	0.18%	124
2013 Q3	$343K	Sell	7,676 -111	-1%	-$4.92K	0.17%	128
2013 Q2	$322K	Buy	+7,787	New	+$341K	0.18%	127

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hanson & Doremus Investment Management's ABBV Position: Q2 2026 in Review

Hanson & Doremus Investment Management increased its AbbVie (ABBV) stake by 5.6% in Q2 2026, buying an estimated $190K and bringing the position to 16,581 shares worth $4.17M. The position accounts for 0.42% of the portfolio, ranked #35.

Hanson & Doremus Investment Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Hanson & Doremus Investment Management held 16,581 shares of AbbVie worth $4.17M as of Q2 2026.
Hanson & Doremus Investment Management bought 883 AbbVie shares in Q2 2026, an estimated $190K.
AbbVie made up 0.42% of Hanson & Doremus Investment Management's portfolio in Q2 2026, its #35 holding.
Hanson & Doremus Investment Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hanson & Doremus Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.